BRIEF-Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab

Reuters
07 Apr
BRIEF-Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab

April 7 (Reuters) - Corcept Therapeutics Inc CORT.O:

  • CORCEPT INITIATES TRIAL OF RELACORILANT PLUS NAB-PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

  • CORCEPT THERAPEUTICS INC - BELLA TRIAL TO ENROLL 90 WOMEN WITH PLATINUM-RESISTANT OVARIAN CANCER

Source text: ID:nBw1r6n8la

Further company coverage: CORT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10